Safety and Humoral Immunogenicity of Different Dose Levels of Ad26.COV2.S as a 2-Dose Regimen in COVID-19 Vaccine-Naïve Healthy Adults: A Phase 3 Randomized Clinical Trial

Background: This study aimed to support the end-of-shelf life specification (2.5 × 10<sup>10</sup> virus particles [vp]) for the standard Ad26.COV2.S dose (5 × 10<sup>10</sup> vp). Methods: This randomized, double-blind Phase 3 study evaluated immunogenicity, reactogenicity, and safety of several Ad...

Ful tanımlama

Kaydedildi:

Detaylı Bibliyografya
Asıl Yazarlar:	Veronica V. Rezelj, Fred Paddenburg, Marie Enajite Diegbe, Julius Nangosyah, Emil C. Reisinger, Weihong Hu, Carla Truyers, Gert Scheper, Mathieu Le Gars, Jenny Hendriks, Frank Struyf, Macaya Douoguih, Hanneke Schuitemaker, Javier Ruiz-Guiñazú
Materyal Türü:	Artigo
Dil:	Inglês
Baskı/Yayın Bilgisi:	MDPI AG 2024-10-01
Seri Bilgileri:	Vaccines
Konular:	Ad26.COV2.S vaccine COVID-19 adult immunogenicity spike-binding antibodies
Online Erişim:	https://www.mdpi.com/2076-393X/12/10/1136
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!

Safety and Humoral Immunogenicity of Different Dose Levels of Ad26.COV2.S as a 2-Dose Regimen in COVID-19 Vaccine-Naïve Healthy Adults: A Phase 3 Randomized Clinical Trial

Benzer Materyaller